1. Home
  2. RELI vs ENSC Comparison

RELI vs ENSC Comparison

Compare RELI & ENSC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Reliance Global Group Inc.

RELI

Reliance Global Group Inc.

HOLD

Current Price

$0.56

Market Cap

5.5M

Sector

Finance

ML Signal

HOLD

Logo Ensysce Biosciences Inc.

ENSC

Ensysce Biosciences Inc.

HOLD

Current Price

$1.07

Market Cap

6.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RELI
ENSC
Founded
2013
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5M
6.3M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
RELI
ENSC
Price
$0.56
$1.07
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
700.3K
452.9K
Earning Date
11-06-2025
11-14-2025
Dividend Yield
5.26%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$13,115,995.00
$4,487,973.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
1.51
52 Week Low
$0.50
$0.86
52 Week High
$3.55
$8.97

Technical Indicators

Market Signals
Indicator
RELI
ENSC
Relative Strength Index (RSI) 41.00 35.99
Support Level $0.54 $0.89
Resistance Level $0.65 $1.10
Average True Range (ATR) 0.05 0.09
MACD 0.01 0.02
Stochastic Oscillator 36.72 48.67

Price Performance

Historical Comparison
RELI
ENSC

About RELI Reliance Global Group Inc.

Reliance Global Group Inc operates as a holding company with diversified interests in the insurance market, as well as other related sectors. The company focuses on growing by pursuing acquisition strategies, initially and focused on wholesale and retail insurance agencies. Its primary strategies is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations, and achieve asset value appreciation while generating interim cash flows. The company generates revenue in the form of commissions.

About ENSC Ensysce Biosciences Inc.

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, tamper-proof opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

Share on Social Networks: